← BackELITE PHARMACEUTICALS INC /NV/ · DrugmakersELTP
Low riskNext report: Around Nov 13 (est.)
The short versionA profitable company with shrinking sales. Insiders are buying.
Going well
- Profitable, keeps 30% of sales as profit
- Sales up 77% last year
- Brings in more cash than it spends
Watch out for
- Sales down 20% in the latest quarter vs a year ago
Money moves
- An insider bought $26K of shares with their own money in the last 30 days
Facts from SEC filings, not a recommendation.
The business over time
Last 12 quarters, from SEC filings
Sales, Jun '26$32.4M-20% vs a year earlier
Sep '23Tap a barJun '26
Last 12 months: $141.0M, up 34% from the 12 months before. Over 5 years, sales grew about 42% a year.
Business quality
The checklist Warren Buffett-style investors use. Annual numbers for 2025.- PassReturn on equity 15%+Earns a lot on the money owners have in the business.76.9%
- PassDebt under half of equityNot relying on borrowed money.0.03x equity
- PassNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.30.1%
- MissProfitable every yearSteady profits, not one good year.6 of 10 years
- PassFree cash flow positiveBrings in more cash than it spends to run and grow.$22.8M
- MissShare count not growingNot diluting owners. Falling means buybacks.+12.4% in 3 years
- PassGross margin 40%+Pricing power: sells for well above what it costs to make.50.4%
- Revenue
- $148.9M
- +77.1% vs prior year
- 5-year growth
- +42.4%/yr
- revenue, per year
- Total debt
- $2.2M
- 0.03x equity
- Current ratio
- 7.34x
- short-term assets / bills due
From annual reports filed with the SEC. A checklist is a starting point for research, not a verdict.
Latest quarter
Quarter ended Jun 30, 2026- Revenue
- $32.4M
- -19.5% YoY
- EPS
- $0.01
- vs -$0.01
- Op. margin
- 23.3%
- -30.7 pts
- Gross margin
- 41.7%
- -26.0 pts
- Free cash flow
- $9.3M
- Share count
- +5.6%
- vs a year ago
Insider rating
Last 90 days
54Mixed
50 is neutral. Buying by more insiders, top executives and bigger stakes raises it. Selling lowers it; pre-planned sales count less.
Weekly insider trend13 weeks agoBoughtSoldThis week
Filing buzz
Last 7 days vs normal
0/ 100
- This week
- 0
- Normal week
- 0.5
- vs normal
- 0.0x
SEC filings of any kind. 50 means a normal week.
Share count growthYearly rate, last 3 years
+2.0%Cash runwayAt last year's cash burn
Cash flow positiveDebt to equityLatest balance sheet: debt compared with what owners have
0.0x · $2.1M debtShares outstandingLatest reported
1.1BNext reportAround Nov 13 (est.)Estimated from the same quarter last year
- Results filedAug 13
- Results filedJun 29
- Results filedFeb 17
- Results filedNov 14, 2025
- Results filedAug 14, 2025
Flags and big holders
Offerings 6 months, flags 12 months, holders 90 days
No offerings, red flags or new big holders. Clean record.
Insider trades
Open-market buys and sells, last 90 days Bought$26K1 insider
Sold$00 insiders
| Insider | Trade | Shares | Avg price | Value | Owns after | Date |
|---|
Barry H DashDirector | Buy | 100K | $0.26 | $26K | 3M | |
- +3.1% of their holdings
- Filed 10 days after
|
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.